Jove
Visualize
Contact Us

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

83
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
83
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

135
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
135
Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

80
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
80
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. New Substituted Molecular Classifications Of Advanced Gastric Adenocarcinoma: Characteristics And Probable Treatment Strategies.
  1. Home
  3. New Substituted Molecular Classifications Of Advanced Gastric Adenocarcinoma: Characteristics And Probable Treatment Strategies.

Related Experiment Video

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K

New substituted molecular classifications of advanced gastric adenocarcinoma: characteristics and probable treatment

Bingzhi Wang1, Chunxia Du2, Lin Li1

  • 1Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Journal of the National Cancer Center
|July 22, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

New immunohistochemistry (IHC)-based classifications for gastric adenocarcinoma (GA) reveal distinct subtypes. These substituted molecular (SM) classifications correlate with varied clinicopathological features, immune microenvironments, and potential treatment strategies for GA.

Keywords:
Advanced gastric adenocarcinomaExpression patternSubstituted molecular classification

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

666
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Related Experiment Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

666
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Area of Science:

  • Oncology
  • Pathology
  • Molecular Biology

Background:

  • Gastric adenocarcinoma (GA) is a heterogeneous malignancy requiring precise classification.
  • Existing molecular classifications overlook GA with primitive enterocyte phenotype (GAPEP), a subtype associated with poor prognosis and liver metastasis.
  • There is a need for novel substituted molecular (SM) classifications based on immunohistochemistry (IHC).

Purpose of the Study:

  • To develop and validate new SM classifications for GA using IHC.
  • To analyze the clinicopathological features, immune microenvironment, and expression of key markers (HER2, VEGFR2) across different GA subtypes.
  • To explore the clinical implications of these new classifications for treatment strategies.

Main Methods:

  • Retrospective analysis of 582 GA cases using IHC staining.
  • Categorization into six SM subtypes: mismatch repair deficient (dMMR), Epstein-Barr virus associated (EBVa), primitive enterocyte phenotype (PEP), epithelial mesenchymal transition (EMT), not otherwise specified/P53 mutated (NOS/P53m), and not otherwise specified/P53 wild-type (NOS/P53w).
  • Evaluation of clinicopathological characteristics, PD-L1, CD8, HER2, and VEGFR2 expression.

    • Main Results:

    • Prevalence: dMMR (5.3%), EBVa (2.2%), PEP (7.6%), EMT (21.0%), NOS/P53m (21.8%), NOS/P53w (42.1%).
    • Survival outcomes varied significantly, with dMMR showing the best survival and NOS/P53m and PEP showing the worst.
    • EBVa subtype patients were younger with higher PD-L1/CD8 expression. EMT subtype showed poor differentiation and increased metastasis. NOS/P53m and PEP subtypes had the highest expression of PD-L1, HER2, and VEGFR2.

    Conclusions:

    • The novel SM classifications based on IHC reveal distinct GA subtypes with unique clinicopathological and molecular profiles.
    • These classifications correlate with differences in patient survival, immune microenvironment, and marker expression.
    • The identified subtypes and their characteristics provide a basis for tailoring clinical treatment strategies in gastric adenocarcinoma.